In a matter of 41 trading days, since the last life-high on February 16, the second wave of the Covid-19 pandemic has caused between 8% -9.8% correction in the benchmark equity indices until April 19.
A year after the onslaught of the global pandemic, FPI inflows, corporate
performance, and news of the vaccines were key to the Indian equity markets’
immunity against Covid-19.
Rising inflation and firming bond yields in the U.S. push down Indian benchmark indices, causing a correction of around 6% from the latest life–highs of February 16.
Though equity MFs witnessed the seventh consecutive month of net outflows in January, AMFI's chief executive says investors will continue to tap MFs as a handy route for wealth creation.
Despite the Survey’s positive tone, the Sensex and Nifty 50 closed in the red, falling nearly 8% in a matter of five trading sessions from their January 21 life–high.
Fears over a new strain of the Coronavirus, discovered in the U.K., hit India's stock market on Monday, with benchmark equities witnessing the hardest fall in the past seven months.
Both the Sensex and the Nifty 50 stage more than 14% recovery. The Sensex market capitalisation is up by nearly ₹7.63 lakh crore with 13.48% monthly growth.
Franklin Templeton India has closed six yield-oriented schemes—which accounted for 63.4% of its total debt-oriented funds’ average AUM. It links the closure to Covid-19-related market dislocations.
Both the BSE Sensex and Nifty 50 plunge nearly 4% intraday as fear grips equity markets after the historic collapse of U.S. crude oil prices on Monday.
